Understanding pharmacokinetics of novel prolonged release dienogest 2 mg / ethinyl-estradiol 0.02 mg oral contraceptive formulation: clinical applications.
Barretta Marta M, Versailles Jacques B E JBE, Bahamondes Luis L, Juliato Cassia T CT et al.
Combined oral contraceptives (COCs) have traditionally evolved through changes in estrogen and progestin type and dose. More recently, drug-delivery technology has emerged as an additional strategy to modify pharmacokinetic (PK) profiles without altering hormonal components. A structured search of MEDLINE and regulatory sources was conducted to review the PK and pharmacodynamic characteristics of a prolonged-release COC containing dienogest (DNG) 2 mg and ethinylestradiol (EE) 0.02 mg, and to explore their clinical implications. Compared with immediate-release formulations, prolonged-release DNG/EE produces delayed peak concentrations, lower plasma peak levels, and reduced intra-day hormonal fluctuations while maintaining comparable overall exposure. Clinical evidence indicates contraceptive efficacy comparable to other COCs, with improved bleeding control compared with an immediate-release formulation. Both the intrinsic endometrial effects of DNG and more stable hormonal exposure may contribute . The formulation also provides antiandrogenic effects that may benefit hirsutism in women with PCOS. The safety profile appears broadly consistent with other low-dose COCs, although the effect on thromboembolic risk remains uncertain. Prolonged-release technology adds a new dimension to contraceptive choice. Further comparative and post-marketing studies are needed to establish its clinical advantages and long-term safety.